Bulk Pharmaceutical API Sources for BIAXIN

Bulk Pharmaceutical API Sources for BIAXIN

Vendor	Vendor Homepage	Vendor Sku	API Url
TCI (Tokyo Chemical Industry)		C2220
Molport		MolPort-002-507-425
Amadis Chemical		A840042
AKos Consulting & Solutions		AKOS015894242

BIAXIN Bulk Active Pharmaceutical Ingredient (API) Sourcing

Last updated: February 19, 2026

This analysis details bulk active pharmaceutical ingredient (API) sources for BIAXIN (clarithromycin), focusing on key manufacturers, geographic distribution, regulatory compliance, and supply chain considerations. Data indicates a concentrated manufacturing base, primarily in China and India, with established players holding significant market share.

What are the primary global suppliers of BIAXIN API?

The bulk API market for BIAXIN is dominated by manufacturers in Asia, with China and India hosting the majority of production facilities. These suppliers cater to both generic drug manufacturers and, in some cases, the originator market.

• China: Multiple chemical and pharmaceutical companies in China produce clarithromycin API. These entities often operate under strict quality control measures to meet international regulatory standards. Key manufacturers include:

  • Zhejiang Medicine Co., Ltd. (ZMC): A significant player in the global API market, ZMC manufactures clarithromycin.
  • Jubilant Life Sciences: While a major Indian pharmaceutical company, Jubilant has manufacturing operations that contribute to the global supply.
  • Other Chinese Manufacturers: A number of other chemical synthesis companies in China supply clarithromycin API, often through B2B platforms and direct export channels. Specific company names can fluctuate based on market dynamics and disclosure policies.

• India: Indian pharmaceutical companies are also substantial producers of clarithromycin API. India's established generic drug industry creates a strong demand for high-quality, cost-effective APIs. Key manufacturers include:

  • Lupin Limited: A global pharmaceutical company with a presence in API manufacturing.
  • Dr. Reddy's Laboratories: A leading Indian pharmaceutical company that produces a range of APIs, including those for macrolide antibiotics.
  • Sun Pharmaceutical Industries Ltd.: Another major Indian firm with API production capabilities.

• Other Regions: While less concentrated, some API production may occur in other regions, often by companies with specialized synthesis capabilities. However, the bulk of supply originates from the aforementioned Asian countries.

What is the regulatory status and compliance landscape for BIAXIN API suppliers?

Regulatory compliance is paramount for BIAXIN API suppliers. Manufacturers must adhere to stringent guidelines set forth by major pharmaceutical regulatory bodies to ensure the safety, efficacy, and quality of their products.

• Good Manufacturing Practices (GMP): All reputable BIAXIN API manufacturers must operate under cGMP (current Good Manufacturing Practices) standards. This includes:

  • FDA (U.S. Food and Drug Administration): Manufacturers supplying to the U.S. market must be registered with the FDA and undergo regular inspections. Drug Master Files (DMFs) are typically submitted for review.
  • EMA (European Medicines Agency): Suppliers for the European market must comply with EMA guidelines and possess Certificates of Suitability to the monographs of the European Pharmacopoeia (CEPs).
  • WHO (World Health Organization): For supply to countries utilizing WHO prequalification, manufacturers must meet WHO GMP standards.

• Pharmacopoeial Standards: API quality is benchmarked against official pharmacopoeial standards:

  • United States Pharmacopeia (USP): Clarithromycin USP monograph defines purity, impurity profiles, and analytical methods.
  • European Pharmacopoeia (Ph. Eur.): Clarithromycin Ph. Eur. monograph provides similar quality specifications.
  • Japanese Pharmacopoeia (JP): For markets adhering to JP standards.

• Impurity Profiling: Regulatory bodies require comprehensive characterization and control of impurities in API. This includes identification, quantification, and toxicological assessment of known and potential impurities arising from the synthesis process or degradation. The acceptable limits for specific impurities are defined by pharmacopoeias and ICH (International Council for Harmonisation) guidelines.

• Site Inspections and Audits: Pharmaceutical companies sourcing BIAXIN API routinely conduct site audits of their API manufacturers. These audits verify GMP compliance, quality systems, and supply chain integrity. Regulatory agencies also conduct independent inspections.

What are the key specifications and quality parameters for BIAXIN API?

Ensuring the quality of BIAXIN API involves adherence to specific chemical, physical, and purity parameters.

• Chemical Name: 6-O-Methylerythromycin.
• Molecular Formula: C38H69NO13.
• Molecular Weight: Approximately 747.96 g/mol.
• Appearance: White to off-white crystalline powder.
• Solubility: Sparingly soluble in water, freely soluble in methanol, ethanol, and acetone.
• Identification: Typically confirmed by Infrared (IR) spectroscopy and High-Performance Liquid Chromatography (HPLC) retention time matching that of a reference standard.
• Assay: The content of clarithromycin is usually determined by HPLC, with specifications typically ranging from 98.0% to 102.0% on an anhydrous and solvent-free basis.
• Water Content: Determined by Karl Fischer titration, with typical limits around 1.0% to 2.0%.
• Residue on Ignition (Sulfated Ash): Measures inorganic impurities, with limits usually below 0.1%.
• Heavy Metals: Limits for heavy metals (e.g., lead, mercury) are typically set at less than 10 ppm or 20 ppm.
• Specific Rotation: A measure of optical purity, with defined ranges. For example, typically between -50° and -56° (calculated on the dried substance).
• pH (of a solution): Usually in the range of 7.0 to 9.0 for a 1% aqueous solution.
• Related Substances (Impurities): This is a critical parameter. HPLC is used to detect and quantify process-related impurities and degradation products. Specific limits are set for individual known impurities and for total impurities. Common impurities include 10-hydroxy clarithromycin, clarithromycin N-oxide, and other related macrolides. For instance, individual unspecified impurities might be limited to NMT (Not More Than) 0.10%, and total impurities to NMT 1.0% or 1.5%.
• Residual Solvents: Limits for residual solvents used in the manufacturing process are defined by ICH Q3C guidelines and specific pharmacopoeial monographs. Common solvents like methanol, ethanol, acetone, and dichloromethane are monitored.

What are the supply chain vulnerabilities and considerations for BIAXIN API?

The global supply chain for BIAXIN API presents several vulnerabilities and necessitates careful management by pharmaceutical companies.

• Geographic Concentration: The heavy reliance on manufacturing in China and India creates potential risks associated with geopolitical events, trade disputes, natural disasters, or regional regulatory changes.
  • Example: A major earthquake or flooding in a key manufacturing region in China could disrupt production for a significant portion of the global supply.
• Single-Source Dependency: Sourcing API from a single manufacturer, even a large one, poses a risk. Any disruption at that specific facility (e.g., equipment failure, quality issue leading to shutdown, labor strike) can halt production.
• Raw Material Availability: The synthesis of clarithromycin relies on specific starting materials and intermediates. Disruptions in the supply of these upstream components, often also sourced from specific geographic regions, can impact API production.
• Logistics and Transportation: Global shipping and air cargo disruptions, port congestion, or increased freight costs can affect timely delivery of API, impacting finished drug production schedules.
• Quality Control and Auditing Burden: While many API manufacturers are compliant, ongoing rigorous quality control and supplier auditing are essential. The cost and resource intensity of these activities are significant.
• Intellectual Property (IP) and Counterfeiting: While clarithromycin is a well-established generic, vigilance against counterfeit API or sub-standard products is necessary, particularly in less regulated markets.
• Environmental Regulations: Increasingly stringent environmental regulations in manufacturing countries can lead to temporary or permanent plant closures, impacting supply.
• Price Volatility: The price of BIAXIN API can fluctuate based on raw material costs, energy prices, manufacturing capacity utilization, and demand.

Pharmaceutical companies mitigate these risks through:

• Dual Sourcing: Qualifying and maintaining relationships with multiple API suppliers in different geographic locations.
• Strategic Inventory Management: Holding buffer stock of critical APIs.
• Robust Supplier Qualification Programs: Comprehensive due diligence, on-site audits, and continuous performance monitoring.
• Contractual Safeguards: Negotiating clear terms regarding delivery, quality, and business continuity.
• Supply Chain Visibility: Utilizing technology to track shipments and monitor supplier performance.

How has the manufacturing landscape for BIAXIN API evolved?

The manufacturing landscape for BIAXIN API has evolved from a more diversified base to a concentrated model, primarily driven by cost efficiencies and economies of scale.

• Shift to Asia: In the late 20th and early 21st centuries, manufacturing of many commodity APIs, including clarithromycin, increasingly shifted from Western countries to China and India. This was due to lower labor costs, less stringent environmental regulations (initially), and government incentives for pharmaceutical manufacturing.
• Consolidation: Over time, the market has seen some consolidation. Larger, well-established players with significant capital investment in state-of-the-art facilities and robust quality systems have gained market share. Smaller or less compliant manufacturers have exited the market.
• Increased Regulatory Scrutiny: As regulatory agencies like the FDA and EMA have increased their focus on API supply chain integrity, manufacturers must demonstrate consistent compliance. This has raised the barrier to entry for new players and pushed existing ones to invest heavily in quality infrastructure.
• Technological Advancements: While the core synthesis routes for clarithromycin are established, manufacturers continue to optimize processes for higher yields, better purity, and reduced waste. This involves advanced chemical engineering and analytical technologies.
• Impact of Generic Competition: The significant competition in the generic clarithromycin market exerts continuous pressure on API manufacturers to maintain competitive pricing while upholding stringent quality standards.

What is the typical lead time for BIAXIN API orders?

Lead times for BIAXIN API orders can vary significantly based on several factors:

• Manufacturer's Production Schedule: Current demand and the manufacturer's existing production commitments play a crucial role.
• Order Volume: Larger orders may require longer lead times due to scale of production.
• Inventory Levels: If the API is in stock at the manufacturer or distributor, lead times can be significantly shorter.
• Customization or Specific Specifications: If specific analytical testing or documentation is required beyond standard specifications, it can extend the lead time.
• Logistics and Shipping: The time required for international shipping, customs clearance, and domestic delivery adds to the overall lead time.

Generally, typical lead times for bulk BIAXIN API orders from established manufacturers can range from:

• 4 to 8 weeks: For standard, in-stock quantities with established supply agreements.
• 8 to 16 weeks: For larger volumes or if the order needs to be scheduled into a production run.
• Up to 6 months: In cases of significant demand spikes, raw material shortages, or if a new manufacturing batch needs to be initiated.

It is essential for procurement teams to engage with suppliers early in the planning process and to clearly define delivery timelines.

Key Takeaways

• BIAXIN API manufacturing is geographically concentrated in China and India, with established players like Zhejiang Medicine Co., Ltd., Jubilant Life Sciences, Lupin Limited, and Dr. Reddy's Laboratories being key suppliers.
• Regulatory compliance with cGMP standards from FDA, EMA, and other national bodies is mandatory, supported by adherence to USP, Ph. Eur., and JP pharmacopoeial monographs.
• Critical API quality parameters include assay (98.0%-102.0%), low levels of related substances (impurities), controlled water content, and absence of heavy metals and residual solvents.
• Supply chain vulnerabilities stem from geographic concentration, potential single-source dependency, raw material availability, and logistics. Risk mitigation strategies include dual sourcing and robust supplier qualification.
• The manufacturing landscape has shifted towards larger, compliant Asian producers, driven by cost efficiencies and increasing regulatory oversight.
• Typical lead times for BIAXIN API orders range from 4 to 16 weeks, but can extend up to 6 months depending on order volume and production scheduling.

Frequently Asked Questions

1. What are the primary risks associated with sourcing BIAXIN API solely from China? Sourcing solely from China exposes a company to geopolitical tensions, trade policy changes, natural disasters affecting manufacturing hubs, and potential regulatory shifts within China impacting production.

2. How can a pharmaceutical company verify the GMP compliance of a new BIAXIN API supplier? Verification involves thorough due diligence, including reviewing the supplier's regulatory inspection history (e.g., FDA Form 483 observations, CEP status), conducting on-site audits, reviewing quality management system documentation, and obtaining product samples for independent testing.

3. What are the implications of a detected impurity above the specified limit in a BIAXIN API batch? An impurity exceeding specified limits can lead to batch rejection, investigation into the root cause by the manufacturer, potential recall of finished drug products, and scrutiny from regulatory agencies. It necessitates a thorough corrective and preventive action (CAPA) plan.

4. Can BIAXIN API be sourced with specific particle size distribution requirements? Yes, while standard specifications exist, API manufacturers can sometimes control particle size through crystallization and milling processes. Specific particle size requirements are typically addressed during the supplier qualification and contractual agreement phase.

5. What is the typical shelf life of BIAXIN API, and how is it determined? The typical shelf life for BIAXIN API is usually 2 to 5 years from the date of manufacture, provided it is stored under recommended conditions (e.g., protected from light and moisture, at controlled room temperature). Shelf life is determined through long-term stability studies conducted by the manufacturer according to ICH guidelines.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-file/drug-master-files-dmfs [2] European Medicines Agency. (n.d.). Certification of suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from https://www.ema.europa.eu/en/human-regulatory/overview/scientific-advice/certification-suitability-monographs-european-pharmacopoeia-cep [3] World Health Organization. (n.d.). Good manufacturing practices (GMP). Retrieved from https://www.who.int/teams/regulation-prequalification/standards-and-sistemas/good-manufacturing-practice [4] United States Pharmacopeial Convention. (n.d.). USP-NF Online. Retrieved from https://online.uspnf.com/ [5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). The European Pharmacopoeia. Retrieved from https://www.edqm.eu/en/european-pharmacopoeia [6] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/page/guidelines [7] Jubilant Life Sciences. (n.d.). API Capabilities. Retrieved from https://www.jubilantlifesciences.com/api/ [8] Lupin Limited. (n.d.). API Business. Retrieved from https://www.lupin.com/api-business/ [9] Dr. Reddy's Laboratories. (n.d.). API Manufacturing. Retrieved from https://www.drreddys.com/careers/pharma-manufacturing/ (Note: Direct link to API business unit may vary; general pharma manufacturing overview used as a placeholder for company's API presence). [10] Zhejiang Medicine Co., Ltd. (ZMC). (n.d.). Product Information. Retrieved from https://www.zmc.com.cn/products/ (Note: Specific clarithromycin API details may require direct inquiry or navigation within the site).